In our exploratory analysis, we demonstrated for tumours with a high uPA/PAI-1 status that only those patients with low NOTCH1 mRNA expression may have a higher benefit from adjuvant chemotherapy whilst patients with high NOTCH1 mRNA expression (22% of the entire cohort, 36% of the uPA/PAI-1 high) have an unfavourable course of disease, suggesting resistance to chemotherapy. The gene discussed is NOTCH1; the disease is neoplasm.